降糖药启动降低华法林抗凝效果但非经药物代谢改变
基于丹麦和苏格兰华法林使用者登记的自控队列研究显示,启动降糖药后INR下降(丹麦队列从2.47降至2.21,均差-0.26;苏格兰队列从2.33降至2.13,均差-0.21)。在10例初治2型糖尿病患者的临床药代试验中,二甲双胍治疗3周和12周未影响CYP3A代谢比值。结论认为降糖药启动与INR降低相关,尤其HbA1c降幅大者,但该效应似与CYP酶活性和华法林代谢无关。
要点
- 慢性华法林使用者启动降糖药后INR平均下降约0.2-0.3,需加强监测。
- HbA1c降幅越大的患者INR下降更明显。
- 二甲双胍治疗3周和12周未改变CYP3A代谢活性。
核心结论
- 慢性华法林使用者启动降糖药与INR降低相关,尤其HbA1c大幅下降者。
- 该INR降低效应似与CYP酶活性及华法林药物代谢无关。
研究设计与样本
- 丹麦和苏格兰登记的自控队列研究,分别纳入982例和44例华法林使用者。
- 临床药代试验纳入10例初治2型糖尿病患者,使用Basel Cocktail探针药。
主要发现
- 丹麦队列启动降糖药后INR从2.47降至2.21,均差-0.26(95%CI -0.35至-0.17)。
- 苏格兰队列启动降糖药后INR从2.33降至2.13,均差-0.21(95%CI -0.52至0.11)。
- 临床药代试验中二甲双胍治疗3周CYP3A代谢比值几何均数比1.12(95%CI 0.95至1.32)。
临床怎么用
- 对启动降糖药的华法林患者应加强INR监测,尤其血糖改善显著者。
- 不应基于CYP酶活性改变来预判华法林剂量调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Drug metabolism might be altered in patients with type 2 diabetes. We aimed to evaluate if initiation of glucose-lowering drugs impacts warfarin efficacy and drug metabolism. METHODS: First, we conducted a register-based self-controlled cohort study on Danish and Scottish warfarin users. Warfarin efficacy (international normalized ratio [INR]) was compared before and after initiation of glucose-lowering drugs. Second, we conducted a clinical pharmacokinetic trial comprising treatment-naïve type 2 diabetes patients. Patients ingested probe drugs for drug-metabolizing enzymes (the Basel Cocktail) before initiating glucose-lowering treatment, and after 3 and 12 weeks of treatment. Drug metabolism, glycaemic control, and inflammation were assessed on each visit. RESULTS: In the Danish and Scottish cohorts (n = 982 and n = 44, respectively), initiating glucose-lowering drugs reduced warfarin efficacy. INR decreased from 2.47 to 2.21 in the Danish cohort (mean difference -0.26; 95% CI -0.35; -0.17) and from 2.33 to 2.13 in the Scottish cohort (-0.21; 95% CI -0.52; 0.11) after initiation of glucose-lowering treatment. This impact on INR was more pronounced among individuals with stronger effects of glucose-lowering treatment. In the clinical pharmacokinetic trial (n = 10), initiating metformin did not affect drug metabolism after 3 weeks (geometric mean ratio of CYP3A metabolic ratio: 1.12 [95% CI: 0.95; 1.32]) or 12 weeks of metformin treatment. Glycaemic control improved during treatment, while inflammation remained low and unchanged during treatment. CONCLUSIONS: In conclusion, initiation of glucose-lowering drugs among chronic warfarin users seems associated with a reduction in INR, particularly among individuals with a large decrease in HbA1c . This effect seems unrelated to CYP enzyme activity and warfarin drug metabolism.
引用
- Dunvald AD, Nielsen F, Olsen DA, et al. Initiation of glucose-lowering drugs reduces the anticoagulant effect of warfarin-But not through altered drug metabolism in patients with type 2 diabetes. Br J Clin Pharmacol. 2023. PMID: 36967527. doi:10.1111/bcp.15725
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。